20 February 2026
Brazil's AI Diagnostic Gold Rush: Pure Global on ANVISA's Hidden Data Hurdles
LATAM MedTech Insights
About
In this episode, we dissect the groundbreaking news from Brazil's health agency, ANVISA. Last week, they launched "Agiliza IA Saúde," a new fast-track approval program for AI-powered medical software. This move could unlock massive opportunities in Latin America's largest market, promising to slash registration times for innovative diagnostic technologies.
While the opportunity is immense, it comes with a critical challenge. The fast-track is gated by a strict compliance audit tied to Brazil's stringent data protection law, the LGPD. This has created a hidden barrier for international companies who are unprepared for the deep level of data traceability and AI "explainability" that ANVISA now requires, potentially derailing their market entry strategies.
**Featured Case:**
A European MedTech scale-up with a market-leading AI diagnostic tool saw Brazil's new program as their golden ticket into LATAM. They were ready for a full-scale launch but were stopped cold during the pre-submission phase. Their pain point: they could not adequately prove compliance with LGPD's data processing and localization requirements, a detail they had completely overlooked. Their entire expansion timeline is now on hold, forcing a costly redevelopment of their data governance framework.
**Key Takeaways From This Episode:**
* What are the specific eligibility criteria for ANVISA's new AI software fast-track program?
* How does Brazil's data protection law (LGPD) directly create new challenges for SaMD manufacturers?
* What is the "right to explanation" and how does it impact AI-based medical devices?
* What are the most common compliance mistakes foreign companies make when entering the Brazilian market?
* Is this new ANVISA policy a sign of a wider regulatory trend across Latin America?
* How can you build a regulatory strategy that balances speed-to-market with deep compliance?
* What level of data traceability and cybersecurity is now considered the standard for Brazil?
Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise in markets like Brazil with advanced AI tools to streamline global market access. We help you navigate complex requirements like ANVISA's new program to ensure a fast and successful launch. To learn more, contact us at info@pureglobal.com or visit us at https://pureglobal.com/.
While the opportunity is immense, it comes with a critical challenge. The fast-track is gated by a strict compliance audit tied to Brazil's stringent data protection law, the LGPD. This has created a hidden barrier for international companies who are unprepared for the deep level of data traceability and AI "explainability" that ANVISA now requires, potentially derailing their market entry strategies.
**Featured Case:**
A European MedTech scale-up with a market-leading AI diagnostic tool saw Brazil's new program as their golden ticket into LATAM. They were ready for a full-scale launch but were stopped cold during the pre-submission phase. Their pain point: they could not adequately prove compliance with LGPD's data processing and localization requirements, a detail they had completely overlooked. Their entire expansion timeline is now on hold, forcing a costly redevelopment of their data governance framework.
**Key Takeaways From This Episode:**
* What are the specific eligibility criteria for ANVISA's new AI software fast-track program?
* How does Brazil's data protection law (LGPD) directly create new challenges for SaMD manufacturers?
* What is the "right to explanation" and how does it impact AI-based medical devices?
* What are the most common compliance mistakes foreign companies make when entering the Brazilian market?
* Is this new ANVISA policy a sign of a wider regulatory trend across Latin America?
* How can you build a regulatory strategy that balances speed-to-market with deep compliance?
* What level of data traceability and cybersecurity is now considered the standard for Brazil?
Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise in markets like Brazil with advanced AI tools to streamline global market access. We help you navigate complex requirements like ANVISA's new program to ensure a fast and successful launch. To learn more, contact us at info@pureglobal.com or visit us at https://pureglobal.com/.